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Background: In pre-clinical models of stem cell therapy, early myocardial cell engraftment predicted late cardiac functional recovery. We sought to 
analyze the effect of myocardial homing of CD34+ cells on clinical outcome in patients with non-ischemic dilated cardiomyopathy (DCM).
methods: In 94 patients with non-ischemic DCM, peripheral blood stem cells were mobilized by daily subcutaneous injections of filgrastim. 
CD34+ cells were collected via apheresis and labeled with technetium. Cells were injected either intracoronary in the artery supplying segments of 
reduced myocardial viability (n=53), or transendocardially in the target areas defined by electro-anatomical mapping (n=41). Nuclear imaging for 
quantitation of myocardial homing of labeled cells was performed 18 hours after the procedure. Good homing was predefined as measured activity 
greater than median value of the general activity. Patients were followed for 1 year.
results: At baseline, patients with good (>median, group A) and poor (≤median, group B) homing did not differ in age, gender, left ventricular 
ejection fraction (LVEF), or plasma levels of creatinine or NT-proBNP. The number of mobilized CD34+ cells used for injection was comparable in 
both groups (98±56 million in group A vs. 101±38 million in group B, P=0.73). Transendocardial cell injection was more frequent in group A (62%) 
than in group B (32%, P=0.01). At year 1, LVEF improved more in group A (+6.2±2.8 %) than group B (+2.7±1.7 %, P=0.01). The same was true for 
6-minute walk test distance (+101±21 m in group A vs. +46±11 m in group B, P=0.01) and levels of NT-proBNP (-733±2411 pg/ml vs. -115±123 
pg/ml, P=0.006). In both groups, we found no significant change in LVEDD (-0.08±0.16 cm in group A vs. -0.06±0.10 cm in group B, P=0.70).
conclusions: In patients with non-ischemic DCM, higher myocardial CD34+ cell homing is associated with superior improvement in ventricular 
function, NT-proBNP levels, and exercise capacity. This suggests that early myocardial cell engraftment translates into long-term clinical benefit in 
this patient cohort.
